Journal List > J Lung Cancer > v.9(2) > 1050720

Jang, Kim, Kwon, Oh, Kim, Kim, Ryu, Yum, Lee, Yong, Lee, Lee, Lee, Jeong, In, and Jung: Female Lung Cancer: Re-Analysis of National Survey of Lung Cancer in Korea, 2005

Abstract

Purpose

Female lung cancers have different clinical features and therapeutic results as compared to those of male lung cancers. The aim of this study was to analyze the differences of Korean men and women with lung cancer.

Materials and Methods

We re-analyzed the results of a national survey of lung cancer conducted by the Korean Association for the Study of Lung Cancer in 2005.

Results

Of the 8,788 patients, 2,124 (24.2%) were female. The mean age at the diagnosis was 62.5 years for the females and 64.8 years for the males and the difference was significant (p<0.001). An age <50 years was more frequent for the women than for the men (16.2% vs. 7.9%, respectively; p=0.001). The stages between genders were different for the patients with non-small cell carcinoma (NSCLC) (p<0.001), but not for the patients with small cell carcinoma. The overall survival time was longer for woman than that for the man (p<0.001). However, the male patients had longer survival for the smokers with adenocarcinoma and the smokers with squamous cell carcinoma. The never smoker female patients had a better survival time than did the smoking female patients, but the male patient’ survival was not influenced by the smoking status. The stage-specific survival rates were better for the women at all stages of NSCLC (p<0.001). The women who received chemotherapy had a longer survival time did the men who received chemotherapy (p<0.001).

Conclusion

Women with lung cancer were relatively overrepresented among the younger patients and they smoked less intensively, raising the question of gender-specific differences in the carcinogenesis of lung cancer. Over-representation of adenocarcinoma was observed in the women regardless of their smoking status. Women with lung cancer had a better prognosis than men; however, the smoking females showed the worst prognosis. Gender and the smoking status are clearly important factors in the therapeutic approach to lung cancer.

References

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55:10–30.
crossref
2. Fiore MC, Novotny TE, Pierce JP, Hatziandreu EJ, Patel KM, Davis RM. Trends in cigarette smoking in the United States. The changing influence of gender and race. JAMA. 1989; 261:49–55.
crossref
3. Visbal AL, Williams BA, Nichols FC 3rd, et al. Gender differences in nonsmall-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004; 78:209–215.
crossref
4. Nobello S, Brahmer JR, Stabile LP, Siegfried JM. Gender-related differences in lung cancer. Pass HI, Carbone DP, Johnson DH, editors. Principles and practice of lung cancer. 4th ed.Philadelphia: Lippincott Williams & Wilkins;2010. p. 353–368.
5. Korean National Statistical Office. Annual report on the cause of death statistic. Daejeon: Korean National Statistical Office;2007.
6. Scientific Committee of Korean Academy of Tuberculosis and Respiratory Disease. The national survey of lung cancer in Korea. Tuberc Respir Dis. 1999; 46:455–465.
7. Kim YC, Kwon YS, Oh IJ, et al. National survey of lung cancer in Korea, 2005. J Lung Cancer. 2007; 6:67–73.
crossref
8. Minami H, Yoshimura M, Miyamoto Y, Matsuoka H, Tsubota N. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest. 2000; 118:1603–1609.
9. de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with nonsmall cell lung carcinoma. J Thorac Cardiovasc Surg. 2000; 119:21–26.
crossref
10. Radzikowska E, Gł az P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol. 2002; 13:1087–1093.
crossref
11. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest. 2005; 127:768–777.
12. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16:481–488.
crossref
13. Badar F, Meerza F, Khokhar RA, et al. Characteristics of lung cancer patients–the Shaukat Khanum Memorial experience. Asian Pac J Cancer Prev. 2006; 7:245–248.
14. Strauss GM, Ahmedin J, McKenna MB, Strauss JA, Cummings KM. The epidemic of smoking-related adenocarcinoma of the lung: the role of the tobacco industry and filtered and low-tar cigarettes: PRS-01. J Thorac Oncol. 2007; 2:S305.
15. Yu IT, Chiu YL, Au JS, Wong TW, Tang JL. Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res. 2006; 66:4961–4967.
crossref
16. Má rquez-Garbá n DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human nonsmall cell lung cancer. Steroids. 2007; 72:135–143.
crossref
17. Rivera MP, Stover DE. Gender and lung cancer. Clin Chest Med. 2004; 25:391–400.
crossref
18. International Early Lung Cancer Action Program Investigators. Henschke CI, Yip R, Miettinen OS. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA. 2006; 296:180–184.
19. Johnson BE, Steinberg SM, Phelps R, Edison M, Veach SR, Ihde DC. Female patients with small cell lung cancer live longer than male patients. Am J Med. 1988; 85:194–196.
crossref
20. Kim HK, Yook DS, Shin HS, et al. Analysis of prognostic factors related to survival time for patients with small cell lung cancer. Tuberc Respir Dis. 2003; 54:57–70.
crossref
21. Kure EH, Ryberg D, Hewer A, et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis. 1996; 17:2201–2205.
22. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res. 1994; 54:5801–5803.
23. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol. 2007; 25:1705–1712.
crossref
24. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage nonsmall-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991; 9:1618–1626.
crossref
25. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in nonsmall cell lung cancer. Clin Cancer Res. 2002; 8:2286–2291.

Figures and Tables

Fig. 1.
Proportion (%) of the pathologic types for the never smokers’ lung cancer. ADC: adenocarcinoma, BAC: brochio-loadenocarcinoma, NSCLC: non-small cell carcinoma, SQCC: squamous cell carcinoma, SCLC: small cell carcinoma.
jlc-9-57f1.tif
Fig. 2.
Proportion (%) of the pathologic types for the smokers’ lung cancer. ADC: adenocarcinoma, BAC: brochioloadeno-carcinoma, NSCLC: non-small cell carcinoma, SQCC: squamous cell carcinoma, SCLC: small cell carcinoma.
jlc-9-57f2.tif
Fig. 3.
Kaplan-Meier curves of the overall survival of patients according to smoking and gender. The never smoker female patients had the best survival time. The male patients’ survival was not influenced by the smoking status. MST: median survival time.
jlc-9-57f3.tif
Fig. 4.
Kaplan-Meier curves for the overall survival of patients with adenocarcinoma. (A) The female patients showed superior survival compared to that of the male patients, and (B) the non-smoker patients showed superior survival compared to that of the smoker patients. MST: median survival time.
jlc-9-57f4.tif
Fig. 5.
Kaplan-Meier curves of overall survival for the patients with squamous cell carcinoma. (A) The male patients showed superior survival compared to that of the non-smoking patients, and (B) the smoking patients showed the superior survival compared to that of the non-smoking patients. MST: median survival time.
jlc-9-57f5.tif
Table 1.
Characteristics of Patients by Gender
  Female Male p-value
No. of patients (%) 2,124 (24.2) 6,664 (75.8)  
Age, yr 62.5 64.8 <0.001
Never smoker, % 79.7 13.3 <0.001
Smoking, pack-yr 33.3 38.3 <0.001
ADC/Non-ADC, % 70.1/29.9 34.6/66.4 <0.001
ECOG 0∼1/3∼4, % 73.2/26.8 75.6/25.4 0.05
Stage, %      
 I∼ II/III/IV 26.5/22.7/50.9 24.5/38.5/37 <0.001
 L/E 49.2/50.8 43.6/56.4 0.087
Treatment, %     <0.001
 Surgery 24.5 21.4  
 Radiotherapy 7.7 7.9  
 Chemoradiotherapy 3.4 6.1  
 Chemotherapy 37.3 38.2  
BSC 27.2 26.5  

ADC: adenocarcinoma, ECOG: Eastern Cooperative Oncology Group, L: limited, E: extensive, BSC: best supportive care.

Table 2.
The Prevalence of Lung Cancer according to the Age
Age Female, No. (%) Male, No. (%) p-value
<30 15 (0.7) 27 (0.4)  
30∼39 75 (3.5) 74 (1.1)  
40∼49 254 (12.0) 424 (6.4) 0.001*
50∼59 434 (20.4) 1,198 (18.0)  
60∼69 677 (31.9) 2,727 (40.9)  
≥70 669 (31.5) 2,214 (33.2)  
Total 2,124 (100.0) 6,664 (100.0)  

* Based on the patients with under 50 years old.

Table 3.
Prevalence (%) of Adenocarcinoma Compared with Non-Adenocarcinoma according to the Age
Age, yr Male Female
Smoker Never-smoker Smoker Never-smoker
≤30 85.7 80.0 77.8
31∼40 70.6 53.8 50.0 75.6
41∼50 56.9 72.2 55.6 79.3
51∼60 39.6 48.2 55.6 70.7
61∼70 29.2 48.5 38.3 79.1
71∼80 27.9 44.2 40.6 66.8
≥80 22.4 29.4 45.2 67.8

Values are presented as percent.

Table 4.
Univariated Survival Analysis according to Gender
  Median survival time, mo (95% CI) p-value
Female Male
Overall 28.4 (25.9∼30.9) 26.7 (25.2∼28.3) <0.001
Never-smoker 29.5 25.2 (23.6∼26.9) <0.001
Smoker 24 (17.7∼30.3) 26.1 (24.4∼27.8) 0.003
Age      
 <70 29.5 28.6 <0.001
 ≥70 24 (21∼26.9) 23.6 (21.2∼25.9) 0.751
Adenocarcinoma 28.5 (25.6∼31.3) 28.4 (26.2∼30.6) <0.001
 Never-smoker 29.5 25.2 <0.001
 Smoker 24 (18.5∼29.5) 28.2 (26.1∼30.4) 0.05
Squamous cell carcinoma 25.6 (17.8∼33.5) 29.6 0.036
 Never-smoker 25.6 (15.9∼35.3) 24.2 (12.5∼35.9) 0.528
 Smoker 23.4 (8.8∼37.9) 29.6 0.165
Small cell carcinoma NR 20.5 0.451
ECOG 0∼1 26.5 (25.8∼27.4) 26.5 (25.4∼27.8) <0.001
ECOG 2∼4 16.4 (11.8∼20.9) 12.6 (10.7∼14.4) 0.089
Stage I∼ III NR NR 0.000
Stage IV 24.7 (21.9∼27.5) 17.7 (15.7∼18.9) <0.001
Treatment group NR 28.4 (27.2∼29.7) <0.001
 Surgery NR NR <0.001
 RT or CRT 27.3 (19.4∼35.3) 24.3 (21.4∼27.2) 0.344
 Chemotherapy 25.8 (23.6∼28) 22.2 (20.4∼24) <0.001
Supportive group 14.7 (10.0∼19.4) 16.3 (11.5∼21.1) 0.290

CI: confidence interval, NR: not reach, ECOG: Eastern Cooperative Oncology Group.

TOOLS
Similar articles